Bexion Pharmaceuticals
Covington
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is developing innovative cures for cancer. Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action. Studies strongly suggest that specific tumor targeting is the result of targeting Phosphatidylserine patches that are characteristic of tumor cells and neovasculature; and that apoptosis results from activation of acid sphingomyelinase, subsequent generation of ceramide, and elevated levels of caspase.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.0M
- Funding stage: Early Stage Venture
- Last round: Grant (Nov 2024)
- Website: bexionpharma.com
- Phone: 859-757-1652
Industries & Categories
Biopharma, Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/bexion-pharmaceuticals-46297 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.